PROTEON THERAPEUTICS, INC. (NASDAQ:PRTO) Files An 8-K Submission of Matters to a Vote of Security Holders

0

PROTEON THERAPEUTICS, INC. (NASDAQ:PRTO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security
Holders
(a)The Companysannual meeting of stockholders was held on
June 20, 2017.
(b)The stockholders elected all of the Companys nominees for
directors and ratified the appointment of Ernst and Young LLP
as the Companys independent registered public accounting firm
for the fiscal year ending December 31, 2017.The tabulation
of votes for each proposal is as follows:
Proposal 1 – Election of Directors
For Withheld Broker Non-Votes
Scott A. Canute 11,017,667 226,380 4,124,217
Tim Haines 11,019,212 224,835 4,124,217
Proposal 2 – Ratification of Independent Registered Public
Accounting Firm
For Against Abstentions
15,329,819 15,079 23,366


About PROTEON THERAPEUTICS, INC. (NASDAQ:PRTO)

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.